First Healthy Volunteer Dosed in Trial Testing ISM001-055 for IPF

First Healthy Volunteer Dosed in Trial Testing ISM001-055 for IPF

313471

First Healthy Volunteer Dosed in Trial Testing ISM001-055 for IPF

The first healthy volunteer has been dosed in a Phase 1 trial evaluating ISM001-055, Insilico Medicine’s artificial intelligence (AI)-discovered therapy candidate for idiopathic pulmonary fibrosis (IPF). “We are very pleased to see Insilico Medicine’s first antifibrotic [treatment] candidate entering into the clinic,” Feng Ren, PhD, Insilico’s chief strategy officer, said in a press release. “We believe this is a significant milestone in the history of AI-powered drug discovery because to our knowledge [ISM001-055] is the…

You must be logged in to read/download the full post.